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SUMMARY
One potential therapeutic strategy for Alzheimer’s
disease (AD) is to use antibodies that bind to small
soluble protein aggregates to reduce their toxic ef-
fects. However, these therapies are rarely tested in
human CSF before clinical trials because of the lack
of sensitive methods that enable the measurement
of aggregate-induced toxicity at low concentrations.
We have developed highly sensitive single vesicle
and single-cell-based assays that detect the Ca2+
influx caused by the CSF of individuals affected
with AD and healthy controls, and we have found
comparable effects for both types of samples. We
also show that an extracellular chaperone clusterin;
a nanobody specific to the amyloid-b peptide (Ab);
and bapineuzumab, a humanized monoclonal anti-
body raised against Ab, could all reduce the Ca2+
influx caused by synthetic Ab oligomers but are
less effective in CSF. These assays could be used
to characterize potential therapeutic agents in CSF
before clinical trials.
INTRODUCTION
Protein misfolding and aggregation underlies a range of neuro-
degenerative diseases, including Alzheimer’s disease (AD).
Monomeric amyloid-b peptide (Ab) is released from the amyloid
precursor protein (APP) by proteolysis, aggregates into a range
of soluble oligomers, and, ultimately, aggregates into insoluble
amyloid fibrils deposited in the brain (Chiti and Dobson, 2017;
Glenner and Wong, 1984; Riek and Eisenberg, 2016). A body
of evidence indicates that Ab oligomers play a key role in the
development of AD by initiating a cascade of biochemical pro-
cesses (including disruption of Ca2+ homeostasis) that ultimately
lead to neuronal death (Arbel-Ornath et al., 2017; Benilova et al.,
2012; Chiti and Dobson, 2017; Haass and Selkoe, 2007). Pico-
molar concentrations of synthetic Ab oligomers can cause
Ca2+ influx into neuronal cells and astrocytes, leading to
oxidative stress and caspase 3 activation, which can result in
apoptosis (Narayan et al., 2014). The soluble aggregates present
within human biofluids have not been studied in such detail, and
indeed Ab can be post-translationally modified and has the po-
tential to interact with other proteins present in the brain (Luo
et al., 2016). Moreover, it is unclear which of the aggregates pre-
sent are most neurotoxic and most directly contribute to the
onset of disease. We have in the past lacked the techniques
needed to measure and quantify effectively such species
present in vivo, for example, in human cerebrospinal fluid
(CSF), where the concentrations are approximately 1 pM (Sav-
age et al., 2014; Yang et al., 2015). This is an important problem
since a number of therapeutic strategies are based on the use of
antibodies or nanobodies to reduce the number of or the toxic
effects of protein aggregates.
Previous work to test potential therapeutic strategies, for
example antibodies, has used aggregates derived from human
sources (Walsh et al., 2002), such as those isolated from the sol-
uble fraction of brain homogenates (Shankar et al., 2008). How-
ever, this method involves several preparative steps and may
lead to soluble aggregates being formed by dissociation from
any insoluble fibrils present. A small number of experiments
have, however, been previously performed using human CSF
without requiring any preparative steps. CSF freely exchanges
with the interstitial fluid in the brain, making it a medium that is
both available for analysis and contains aggregates formed
within a living individual. These experiments have shown that
the aggregates present in CSF can induce long-term potentia-
tion deficit in brain slices which can be suppressed by the addi-
tion of antibodies raised against Ab (Klyubin et al., 2008; Walsh
et al., 2002). CSF from individuals diagnosed with AD has also
been shown to cause cell death, which can be reduced signifi-
cantly by the addition of physiological amounts of extracellular
chaperones (Yerbury and Wilson, 2010).
RESULTS
We have previously developed an extremely sensitive and high-
throughput assay based on the quantitative measurement of
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oligomer-induced Ca2+ influx into hundreds of surface immobi-
lized single lipid vesicles (Flagmeier et al., 2017) (Figure 1A).
We have also shown that even low levels of Ab42 oligomers
can induce Ca2+ influx into neuronal cells by local dosing with
a nanopipette (Figure 1B) (Drews et al., 2016). Local dosing re-
duces the diffusion time to the cell surface, leading to detectable
Ca2+ influx at low picomolar concentrations of oligomers that is
comparable to the concentration of species present in CSF.
We have also recently developed a Thioflavin-T (ThT)-based im-
aging method to count the total number of ThT-active species
in CSF using sensitive single-molecule fluorescence measure-
ments (Horrocks et al., 2016) (Figure 1C). Herein we describe
how these methods have been used in a series of experiments
to characterize the protein aggregates present in the CSF of in-
dividuals affected with AD (AD CSF) and control individuals
(HC CSF). We have also tested the effectiveness of a single-
chain nanobody raised against the Ab peptide, the extracellular
chaperone clusterin, and bapineuzumab (a humanized mono-
clonal antibody that was recently used in an unsuccessful AD
drug trial) (Blennow et al., 2012; Liu et al., 2015; Salloway
et al., 2014; Vandenberghe et al., 2016) at reducing the Ca2+
influx induced by samples of CSF.
We first carried out experiments using the high-throughput
vesicle assay or the cell assay to measure the extent of Ca2+
influx induced by samples of AD CSF and HC CSF. We detected
no difference in the extent of Ca2+ influx between these two sets
of samples (Figures 1D and 1E; Tables S1 andS2). A separate set
of experiments also showed no significant difference in the num-
ber of ThT-active species detected in AD CSF and in HC CSF
(Figure 1F; Table S3). Previous work using ELISA-based detec-
tion of the total number of aggregates in CSF also showed no
clear difference between AD and HC samples (Savage et al.,
2014; Yang et al., 2015), a result consistent with our findings.
Together, these data suggest that comparable numbers of spe-
cies in AD CSF and in HC CSF cause Ca2+ influx.
To identify which species present in the CSF might be respon-
sible for the Ca2+ influx, we added clusterin to ADCSF and to HC
CSF (Figures 2 and S1). Clusterin is an extracellular chaperone
known to bind misfolded and aggregated proteins at sub-stoi-
chiometric concentrations compared to the monomer concen-
tration (Yerbury et al., 2007). Additionally, multiple clusterin
molecules were found to bind to each Ab oligomer (Narayan
et al., 2011, 2012). Moreover, in previous work, we determined
that 100 pM clusterin halved the Ca2+ influx induced by recombi-
nant Ab42 oligomers (Flagmeier et al., 2017). This result shows
that clusterin has a very high affinity for oligomers of Ab and, in
our experiments with CSF, we used clusterin concentrations
more than 100 times greater than 100 pM. Clusterin was very
effective at suppressing the Ca2+ influx induced by CSF as
measured using the vesicle assay (Figures 2A and S1A) and cell
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Figure 1. Biophysical Methods Used Here
to Study Properties of Human CSF
(A) Quantitative ultrasensitive single vesicle assay
to assess the ability of species (e.g., Ab42 aggre-
gates or the species present in human CSF) to
permeate the vesicle membrane. Hundreds of
vesicles filled with the Ca2+ sensitive dye Cal-520
act as optochemical probes and are tethered to a
PLL-PEG-coated glass coverslip using biotin-
neutrAvidin linkage. The addition of species able to
penetrate the membrane and hence enable Ca2+
influx from the surrounding solution results in a
change of the fluorescence intensity that can be
measured using total internal reflection micro-
scopy (TIRFM) (see Experimental Procedures for
details).
(B) Scanning ion conductance microscopy
approach to assess the ability of samples (e.g.,
Ab42 aggregates or human CSF) to permeate the
cell membrane. Upon local delivery of the sample
by a nanopipette to the surface of an individual
astrocyte loaded with the Ca2+ sensitive dye
Fluo-4, a change in fluorescence intensity can be
detected as a result of the permeation of the cell
membrane.
(C) Single aggregate visualization through
enhancement (SAVE) imaging using the dye ThT
to measure the number of cross b-sheet containing
species in a sample (e.g. humanCSF). The sample is
added on a passivated glass slide, and the number
of fluorescent species is measured using TIRFM.
(D)Comparisonof the influxofCa2+ ions intovesicles
caused by CSF samples from healthy individuals
(HC CSF) and individuals affected with AD (AD CSF). The difference between Ca2+ influx-induced AD CSF and HC CSF are not significant. Error bars, SEM.
(E) Comparison of the Ca2+ influx into astrocytes caused by HC CSF and AD CSF. Error bars, SEM.
(F) Comparison of the number of b-sheet containing species in HC CSF and AD CSF. Error bars, the 25th and the 75th percentiles. Full statistics for all
experiments are summarized in Tables S1, S2, and S3.
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assay (Figure 2C). That clusterin prevents this Ca2+ influx in both
assays suggests that protein aggregates present in CSF are
responsible for the Ca2+ influx. Furthermore, since clusterin is
already present in CSF at a concentration of about 90 nM both
for individuals affected with AD and for HC (Vranova´ et al.,
2014), this result suggests that in CSF such concentrations are
not high enough to be totally effective at reducing Ca2+ influx.
This finding is in agreement with a previous report that the addi-
tion of higher concentrations of clusterin could reduce the toxic
effects on cells induced by CSF (Yerbury and Wilson, 2010).
We then tested the effectiveness of a single-chain nanobody
Nb3, raised against the Ab peptide, at reducing CSF-induced
Ca2+ influx. Nb3 binds to the epitope 17–28 of the Ab peptide
with a measured dissociation constant for the monomeric pro-
tein of 13 nM. We have previously shown using the vesicle assay
that Nb3 reduces the Ca2+ influx induced by recombinant Ab42
oligomers in the absence of CSF and that approximately
18 nM Nb3 was needed to halve the influx (Flagmeier et al.,
2017). We also found that the addition of Nb3 to Ab42 oligomers
significantly reduced the Ca2+ influx in the cell assays (Drews
et al., 2016). In these experiments, we pre-incubated the AD
or HC CSFs with 150 nM Nb3 for 15 min and then performed
experiments using our vesicle and cell assays (Figures 2B, 2D,
and S1B). These experiments show that Nb3 is able to reduce
the extent of Ca2+ influx induced by samples of AD CSF and
HC CSF. In a control experiment we showed that the addition
of a GFP antibody caused no significant reduction in Ca2+ influx
(Figure S1C). Moreover, the addition of the Nb3 nanobody did
not detectably alter the number of ThT-active species (Figure S2),
indicating that the addition of the nanobody does not lead to the
disaggregation of the aggregates within the timescale of our ex-
periments, approximately 15 min. The observation that Nb3 can
reduce the Ca2+ influx caused by Ab oligomers and also by CSF
both in the vesicle and in the cellular assays suggests that at
least a portion of the influx-inducing species present in CSF con-
tains the amino acids 17–28 of the Ab sequence. Presumably,
Nb3 binds to the species that are potent at inducing Ca2+ influx
and thereby reduces or prevents their interaction with the mem-
branes of vesicles or cells.
Next, we probed the efficacy of bapineuzumab, which is
a bivalent antibody that binds soluble Ab monomer and
oligomers at the N terminus (Miles et al., 2013). Using recombi-
nant Ab42 oligomers, we found that 90 nM bapineuzumab
was required to halve the influx of Ca2+ ions in the vesicle assay
(Figures S3A and S3B). Using the vesicle assay we found that
150 nM bapineuzumab caused a relative decrease of 70%
in the Ca2+ influx (Figure 3A), and that 1 mM bapineuzumab
reduced the Ca2+ influx completely (Figure S3C). Bapineuzu-
mab also prevented Ca2+ influx in the cell assay (Figures 3B
and 3D). We then tested 150 nM bapineuzumab on samples
of AD CSF and of HC CSF. Addition of the antibody did not
detectably alter the number of ThT-active species (Figure S2),
indicating that the addition of bapineuzumab does not signifi-
cantly alter the number of b-sheet containing species within
the timescale of our experiments (Table S3). In the vesicle
assay, using an antibody at a concentration of 150 nM, we
observed an insignificant relative decrease in the Ca2+ influx
induced by AD CSF and HC CSF of 12% (Figures 3B and
S3D). A 10-fold higher concentration of bapineuzumab, 1 mM,
caused a relative decrease in Ca2+ influx of 75% (absolute
decrease 18%) (Figures 3C and S3E). However, we observed
no reduction in Ca2+ influx in the cellular assay at either anti-
body concentration (Figures 3E and 3F). In the cell assay, this
higher antibody concentration is presumably still insufficient
to prevent the interaction with the cell membrane, possibly
because the aggregates have a higher affinity for the cell mem-
brane than for the membrane of a vesicle. Overall, the results of
the single vesicle experiments show that higher bapineuzumab
concentrations are needed to reduce the extent of Ca2+ influx
caused by CSF samples compared to the concentration
needed to counteract the effect of synthetic Ab42 oligomers
in buffer solution. This reduced effectiveness of bapineuzumab
in the inhibition of CSF-induced Ca2+ influx can have a number
of causes including (1) molecular crowding and non-specific
binding to a multitude of components present in CSF, which
might reduce the effective interaction between the species
causing Ca2+ influx and the antibody; (2) the morphology of
the species present that are responsible for Ca2+ influx in
CSF might be different from the species in the experiments
with purified Ab; (3) there might be post-translationally modified
species of Ab present in CSF in which the binding epitope
of bapineuzumab is absent or inaccessible to the antibody.
A combination of these effects could reduce the binding of
the antibody to the aggregates, and as a consequence bapi-
neuzumab is less effective at reducing the Ca2+ influx induced
by CSF.
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Figure 2. Assessing the Ability of Chaperones and Nanobodies to
Counteract the Influx of Ca2+ Ions Resulting from the Addition of
Aliquots of Human CSF
(A and B) Inhibition of the influx of Ca2+ ions into individual vesicles caused
by AD CSF by clusterin (150 nM) (A) and the nanobody Nb3 (150 nM) (B).
(C and D) Inhibition of the influx of Ca2+ ions into astrocytes caused by human
CSF of individuals suffering from AD by clusterin (25 nM) (C) and the nanobody
Nb3 (150 nM) (D). The statistical data for the experiments are summarized in
Tables S1 and S2. Error bars, SEM.
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DISCUSSION
The mechanisms by which amyloid aggregates cause toxic
effects and neuronal cell death remain a topic that is under
investigation. One commonly proposed mechanism is that ag-
gregates permeabilize membranes, leading to altered calcium
homeostasis and, ultimately, to cell death. However, aggregates
can also act by a range of other mechanisms such as by causing
oxidative stress, neuroinflammation, or synaptic dysfunction.
It is therefore extremely important to develop and apply tech-
niques that explore the significance of particular molecular
processes that are likely to contribute to the development of
AD in humans.
The experiments described above show that human CSF can
induce Ca2+ influx in our assays using both single vesicles and
astrocytes. In addition, our results show that Nb3 and bapineu-
zumab, both of which were designed to bind to the Ab peptide,
can both inhibit this Ca2+ influx. Interestingly, we detected no
significant difference in the number of ThT-active species (an
indication of b-sheet containing aggregates) or between Ca2+
influx induced by aliquots of AD CSF and HC CSF. These results
are in agreement with the results of ELISA measurements, using
the same antibody to capture and detect aggregates (Yang et al.,
2015). This result suggests that the total number of the aggre-
gates by itself is not the critical factor in the onset of AD, but
that other factors such as the nature of the aggregates and their
effects are also important.
Our results, however, suggest that the other components pre-
sent in CSF interact with clusterin, Nb3 and bapineuzumab,
making them less available to bind the oligomers, or to compete
for binding to the aggregates or that the oligomers present are
different in their structure or composition from the synthetic
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Figure 3. Assessing the Ability of the Anti-
body Bapineuzumab to Reduce the Ca2+
Influx Resulting from the Addition of Ali-
quots of Human CSF
(A and B) Inhibition of the influx of Ca2+ ions into
individual vesicles caused by aggregates of re-
combinant Ab42 (A) or resulting from the addition of
aliquots of AD CSF by bapineuzumab (150 nM) (B).
(C) The inhibition of the influx of Ca2+ ions into
individual vesicles resulting from the addition of
aliquots of CSF by a high concentration of the
antibody bapineuzumab (1 mM).
(D and E) Inhibition of the Ca2+ influx into astro-
cytes caused by aggregates of synthetic Ab42 (D)
or resulting from the addition of aliquots of human
CSF by the antibody bapineuzumab (150 nM) (E).
(F) The inhibition of the Ca2+ influx resulting from
the addition of aliquots of human CSF into astro-
cytes by a high concentration of bapineuzumab
(1 mM). The statistical data for these experiments
are summarized in Tables S1 and S2. Error
bars, SEM.
Ab42 oligomers. This means that the
levels of clusterin in CSF are not suffi-
ciently high to suppress fully the Ca2+
influx. Higher concentrations of bapineu-
zumab or Nb3 are required to bind to the oligomers and suppress
the extent of Ca2+ influx caused by CSF compared to the species
present in buffer solutions. Bapineuzumab is effective at
reducing the Ca2+ influx caused by CSF in our vesicle assay,
but only at a concentration approximately 100-fold higher than
that used in the clinical trial (Goure et al., 2014). If the effects
that we observe in CSF reflect those within the brain, this sug-
gests that high concentrations of the antibody (or perhaps higher
affinity and more selective antibodies) are required to sequester
fully the potentially toxic aggregates. Our in vitro assays provide
a high-throughput platform to determine if a given antibody is
able to reduce the Ca2+ influx caused by CSF and the concentra-
tion required for it to be effective. This technique can be applied
to any therapeutic strategy that targets protein aggregates. It is
possible that more effective therapies could be more rapidly
developed and optimized if they are tested on humanCSF before
performing costly clinical trials.
EXPERIMENTAL PROCEDURES
Ab42 Aggregation
For the cell assays, Hilyte Fluor 647 Ab42 (Cambridge Bioscience LDT) was
aggregated as described previously (Drews et al., 2016).
Ab Nanobody and Clusterin
Nb3 is an Ab-specific nanobody isolated from a llama and was prepared as
described previously (Drews et al., 2016). Clusterin was obtained as previously
described (Drews et al., 2016; Wilson and Easterbrook-Smith, 1992).
Bapineuzumab Equivalent Antibody
The bapineuzumab equivalent antibody was prepared as described
in its U.S. patent (US 7179892 B2) in 25 mM histidine, 7% sucrose,
and 0.02% polysorbate 80 (pH 6.0) at 48 mg/mL. Endotoxin levels
were < 0.005 (EU/mg).
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Single Aggregate Visualization through Enhancement Imaging
All CSF samples were imaged with the single aggregate visualization through
enhancement (SAVE) method as previously described (Horrocks et al., 2016).
In short, a ThT stock solution was prepared in DMSO, diluted into PBS, and
filtered (0.02-mmfilter, Whatman) with the stock solution prepared daily. Borosil-
icate glass coverslips were cleaned in an argon plasma cleaner (PDC-002,
Harrick Plasma) and coated with poly-(L)-lysine (PLL) for at least 1 hr. The PLL-
coated surfaces were washed with PBS before the sample was applied. CSF
samples were diluted 10-fold into PBS with a final concentration of 5 mM ThT.
Eachsamplewas incubatedon thecoverslip for 10minprior to imaging toensure
fixation of the species on the surface. The samples were imaged using a home-
built total internal reflection fluorescence (TIRF) microscope. ThT was excited
with a 405-nm laser (Oxxius LaserBoxx, LBX-405-100-CIR-PP) aligned to the
optical axis of a 1.49 NA TIRF objective (APON60XO TIRF, Olympus, product
number N2709400). Imaging was performed in TIRF mode on an inverted
Olympus IX-71 microscope with an automated stage (Prior Scientific). The fluo-
rescence signalwas recorded onanEMCCDcamera (Evolve 512, Photometrics)
operating in frame transfermode (EMGainof 11.5 e/ADUand250ADU/photon)
after being separated from the excitation light by a dichroic (Di01-405/488/
532/635, Semrock) and a filter (BLP01-488R-25, Semrock). Each pixel was
206nm in length. For each dataset, 33 3 image gridsweremeasured from three
different areas of the coverslip with set grid distances to prevent user bias. Im-
ages were recorded at 50-ms exposure and 100 frames each field of view in
the blue channel (ThT emission). Data analysis was performed as previously
described (Horrocksetal., 2016)using ImageJsoftware, averagingall 100 frames
and using the ‘‘FindMaxima.’’ The noise tolerance for all measurements was set
to 1,000 fluorescent counts. The number of total events was then divided by the
image area to give the average number of aggregates per micrometer squared.
CSF Samples
Control CSF samples were collected by lumbar puncture from 6 cognitively
normal individuals (aged 49–68 years) and 6 individuals with an AD diagnosis
(aged 51–68 years). A standardized protocol for the collection and storage of
CSF was followed. In short, lumbar puncture in the L3/L4 interspace was per-
formed between 9 a.m. and 12 a.m. to collect 15 mL of CSF in sterile polypro-
pylene tubes. The samples were de-identified, spun at 3,000 rpm for 10 min,
and divided into aliquots each containing 1 mL that were frozen on dry ice
and stored at 80C in 1.5 mL capacity LoBind micro-centrifuge tubes
(Eppendorf, Germany). Sample collection, centrifugation, and freezing was
completed within 1 hr. CSF Ab1-42, T-tau, and P-tau181 were quantified with
sandwich ELISAs (INNOTEST b-amyloid1-42, hTAU-Ag; Fujirebio Europe,
Belgium). Intra-assay coefficients of variation were below 10%. All controls
had no cognitive symptoms and a normal CSF T-Tau/Ab1-42 ratio < 0.52. Pa-
tients with AD had CSF Ab1-42 < 600 ng/L and T-tau > 350 ng/L. Study proto-
cols were approved by the Queen Square ethics committee (references
12_LO_1504 & 12_LO_005), and all individuals gave written informed consent.
The AD CSF used for the cell assays was collected by lumbar puncture from
patients who sought medical advice because of memory problems. The sam-
ples were de-identified and aliquoted into 0.5 mL aliquots in polypropylene
cryo tubes following centrifugation at 2,200 3 g and stored at 80C pending
experimental use. CSF Ab1-42, T-tau and P-tau181 were quantified with sand-
wich ELISAs (INNOTEST b-amyloid1-42, hTAU-Ag and Phospho-Tau [181P],
respectively). All measurements were performed in one round of analyses
using one batch of reagents by board-certified laboratory technicians. Intra-
assay coefficients of variation were below 10%. All AD positive samples had
protein levels of Ab1-42 < 600 ng/L, T-tau > 350 ng/L and P-tau181 > 80 ng/L
according to Toledo et al. (2015). The study protocol was approved by the
regional ethics committee at the University of Gothenburg.
Astrocyte Dosing Experiments
Astrocyte dosing experiments were performed as described previously (Drews
et al., 2016) using rat mixed glial preparations. CSF was used undiluted for all
dosing experiments. When pre-incubated with clusterin or an anti-/nanobody,
the incubation time was 15–30 min before starting experiments, and concen-
trated solutions of reagents were used so there was negligible, less than 2%
dilution for all experiments apart from the 1,000 nM bapineuzumab experi-
ment, where there was 10% dilution.
Single Vesicle Assay
Preparation of Cal-520-Filled Vesicles. Vesicles with a mean diameter of
200 nm were prepared by freeze-and-thaw cycles combined with extrusion
as previously described (Flagmeier et al., 2017). Briefly, chloroform stocks of
16:0-18:1 PC (10 mg/mL) and 18:1-12:0 biotin PC (1 mg/mL) were mixed
such that the ratio of lipid to biotinylated lipid was 100:1 before the chloroform
was removed under vacuum overnight. The lipid mixture was then hydrated in
HEPES buffer (50 mM [pH 6.5]) with 100 mMCal-520. Five freeze-and-thaw cy-
cles were performed using a water bath and dry ice. The lipid solution was
extruded 10 times through a membrane with a size cutoff of 200 nm. Size-
exclusion chromatography was performed using a Superdex 200 to remove
free dye from the surrounding solution. Finally, the size of the vesicles was
determined using a Zetasizer (Zetasizer Nano ZSP, Malvern Instruments).
Vesicle Immobilization on a PEGylated Glass Surface. Glass coverslips were
cleaned by sonicating in 2% (v/v) Hellmanex III in water for 10 min followed by
sonicating twice in water and twice in methanol for 10 min each (Flagmeier
et al., 2017). Then the coverslips were dried under a nitrogen stream for
5 min and plasma cleaned in an argon plasma cleaner (PDC-002, Harrick
Plasma) for 30 min. The sample chambers were made by affixing Frame-
Seal incubation chambers onto the glass slides. For homogeneous surface
treatment, 50 mL of a mixture of 100:1 PLL-g-PEG and PLL-g-PEG biotin
(both 1 g/L) in HEPES buffer (50 mM, pH 6.5) was added to the coverslip inside
of the chamber and incubated for 30min. The surface was washed three times
with filtered HEPES buffer. Then, a solution of NeutrAvidin (50 mL of 0.1 mg/mL
in MilliQ) was added and incubated for 15 min, and washed 3 times. Finally,
50 mL of the solution containing vesicles was added to the coverslip and incu-
bated for 30 min before washing carefully at least 5 times with reaction buffer.
Total Internal Reflection Fluorescence Microscope for Single Vesicle Experi-
ment. The measurements of Ca2+ influx into individual vesicles was per-
formed using a home-built total internal reflection fluorescence microscope
(TIRFM) based on an inverted Olympus IX-71 microscope. A 488-nm laser
(Toptica, iBeam smart, 200 mW, Germany) beam was expanded and focused
on the back focal plane of the 603, 1.49 NA oil-immersion objective lens
(APON60XO TIRF, Olympus, N2709400) to excite the Cal-520 dye incorpo-
rated into the vesicle. The emerging fluorescence was collected by the same
objective. The emission beam was separated from the excitation beam by
a dichroic (Di01-R405/488/561/635, Semrock), passed through a set of filters
(BLP01-488R, Semrock and FF01-520/44-25, Semrock), and imaged onto an
air-cooled EMCCD camera (Photometrics Evolve, EVO-512-M-FW- 16-AC-
110). Excitation power density was fixed to 10 W/cm2 for 50 frames with a
scan speed of 20 Hz and bit depth of 16 bits.
Measurement of the Change in Fluorescence Intensity in Individual Vesicles.
Hundreds of single vesicles tethered to coverslips via biotin-neutrAvidin link-
age were incubated with 50 mL of HEPES buffer (50 mM [pH 6.5]) and imaged
as previously described (Flagmeier et al., 2017). Just before the imaging, the
HEPES buffer was replaced with 50 mL Ca2+ containing buffer solution Leibo-
vitz’s L-15 (L15). 16 different fields of view were recorded under three different
conditions (background; in the presence of CSF or a solution containing re-
combinant protein aggregates; and after the addition of ionomycin, respec-
tively). The distance between each field of view was set to 100 mm and was
automated (bean-shell script, Micromanager) to avoid any user bias. First, im-
ages were acquired in the presence of only L15 buffer, which we denote as
blank (Fblank). For each field of view, 50 images were taken with an exposure
time of 50 ms. Thereafter, a solution of a sample was added and incubated
for 10 min before images of the exact same fields of view were recorded
(Fsample). Next, 10 mL of a solution of ionomycin was added to the coverslip
and incubated for 5 min, and, subsequently, images of the vesicles were
acquired in the same fields of view.
Data Analysis and Quantification of the Extent of Ca2+ Influx. The recorded
images were analyzed using Fiji to determine the fluorescence intensity of
each spot under the three different conditions, namely background (Fblank),
in the presence of the sample (Fsample), and after the addition of ionomycin
(FIonomycin). The relative influx of Ca
2+ into an individual vesicle due to aggre-
gates of the Ab42 peptide was then determined using the following equation:
Ca
2+
influx =
Fsample  Fblank
FIonomycin  Fblank
: (Equation 1)
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Single Vesicle Assay Using CSF. For our single vesicle analysis, we took
15 mL of CSF and diluted it two times in the coverslip with 15 mL L15
buffer and incubated for 10 min. Then the change in fluorescence intensity
was measured as described above.
Single Vesicle Assay Using CSF with Antibodies or Nanobodies. Indicated
concentrations of nanobodies and antibodies were added to samples of CSF
and incubated for 15 min before we performed measurements of the change
in fluorescence intensity in single vesicles as described above. The dilutions
were performed in a manner such that the CSF sample incubated with the ves-
icles was diluted by a factor of two to allow direct comparisons of themeasure-
ments in the absence and presence of antibodies. Comparisons between the
samples were made with a two-sample t test using Origin9.
Preparation and Purification of Recombinant Ab42. The recombinant Ab42
(M1-42) peptide (MDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGG
VVIA), here called Ab42, was used for the vesicle assay experiments and pre-
pared as describe previously (Flagmeier et al., 2017; Hellstrand et al., 2010).
Briefly, the purification involved sonication of the cells, ion exchange chroma-
tography, and size-exclusion chromatography. Purified samples were ali-
quoted, lyophilized, and stored at 80C. For each experiment, solutions of
monomeric recombinant Ab42 were prepared by dissolving the lyophilized
Ab42 peptide in 6 M GuHCl and then purifying the protein using a Superdex
75 10/300 GL. The center of the elution peak was collected, and the peptide
concentration was determined from the absorbance of the integrated peak
area using ε280 = 1,490 L mol
1cm1.
Aggregation Conditions for Recombinant Ab42. Aliquots of monomeric Ab42
were diluted with buffer to a concentration of 2 mM in low-binding Eppendorf
tubes on ice before individual samples were then pipetted into multiple wells
of a 96-well half-area plate. Then the plate was incubated under quiescent
conditions at 37C, and aliquots for measurements of Ca2+ influx were taken
at a time point corresponding to the end of the lag phase (approximately
70 min) as previously described (Flagmeier et al., 2017).
Measurement of the Ca2+ Influx Caused by Ab42. Aliquots were taken from
an aggregation reaction of recombinant Ab42 corresponding to the end of
the lag phase. To measure the change of the fluorescence intensity in the sin-
gle vesicle assay, we diluted the sample to 5 nM with L15 buffer as described
previously.
Single Vesicle Assay Using Ab42 with Antibodies or Nanobodies. Indicated
concentrations of nanobodies and antibodies were added to an aliquot
taken from an aggregation reaction of recombinant Ab42 and incubated
for 15 min. The change in the fluorescence intensity was measured as
described above.
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